A Phase 1 interventional study of ODM-106 and Placebo in Healthy Volunteer Study, sponsored by Orion Corporation, Orion Pharma. Completed at 1 site in Germany. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-12-23.
Sponsored by Orion Corporation, Orion Pharma · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The study is a dose escalation study with 8 planned dose levels. The study is a 4-period crossover design where each healthy volunteer will be randomised to receive three dose levels of ODM-106 (single doses) and one dose of placebo. The study will look at the pharmacokinetics (how the body handles the drug) and pharmacodynamics (how the drug affects the body) of ODM-106.
Eight planned dose levels of ODM-106 will be compared with placebo.There will be 2 panels of subjects with 4 dose levels in each panel. Subjects will be randomised to receive 3 dose levels of active treatment (single doses) and 1 dose of placebo. The dose levels will be escalated from the smallest dose upwards within the study and within the study subject. A third panel of 8 subjects may be included to investigate further dose levels of ODM-106, investigate the effect of taking ODM-106 with food or to compare two different formulations of ODM-106. For an individual subject, the study will consist of a screening period (maximum 4 weeks), 4 study treatment periods with a wash-out period between each study treatment administration and a post-treatment period of about 2 weeks.
The study duration for an individual will be approximately 12-16 weeks. Blood samples will be collected for the assessment of the concentration of ODM-106 and its metabolite.Plasma samples and cumulative urinary samples will be collected for metabolite screening. Safety will be assessed by a 12-lead electrocardiogram (ECG), continuous ECG monitoring, Holter ECG, supine and orthostatic blood pressure and heart rate, body temperature, physical examination, electroencephalogram (EEG), laboratory safety assessments and adverse events. Sedation and psychomotor tests and a quantitative EEG will also be performed.
Orion Corporation, Orion Pharma is the lead sponsor of 101 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Oral capsules dosage 2-800mg once daily for one day
Drug: ODM-106
Oral capsules given once daily for one day
Drug: Placebo
Single oral escalating doses of ODM-106 will be administered. Each subject will participate in 4 study periods and will therefore receive 3 single doses of ODM-106 and one single dose of placebo.
Single oral escalating doses of ODM-106 will be administered. Each subject will participate in 4 study periods and will therefore receive 3 single doses of ODM-106 and one single dose of placebo.
Number of Participants With Adverse Events as a Measure of Safety. Number of Participants With Adverse Events Related to Tolerability.
Clinically relevant changes from baseline in safety laboratory assessments (haematology, clinical chemistry, urinalysis), vital signs (pulse and heart rate), 12 lead electrocardiograms, Holter electrocardiograms, telemetry, physical examination.
Time frame: From screening up to 16 weeks
Peak Plasma Concentration (cMax) of ODM-106
cMax of ODM-106 after single dosing of either Capsule B or Capsule A
Time frame: Pre-dose and 15, 30 and 45 min, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 48, 72 and 96 hours post dose at each dose level.
Area Under the Plasma Concentration Versus Time Curve (AUC) of ODM-106
AUC of ODM-106 after single oral dosing of either Capsule B or Capsule A.
Time frame: Pre-dose and 15, 30 and 45 min, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 48, 72 and 96 hours post dose at each dose level. Urine sampling, pre-dose and for 24 hours post dose at each dose level
Time to Peak Plasma Concentration (Tmax) of ODM-106
tmax of ODM-106 after single oral dosing of Capsule B or Capsule A
Time frame: Pre-dose and 15, 30 and 45 min, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 48, 72 and 96 hours post dose at each dose level
Elimination Half-life of ODM-106
Elimination half-life of ODM-106 after single dosing of either Capsule B or Capsule A
Time frame: Pre-dose and 15, 30 and 45 min, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 48, 72 and 96 hours post dose at each dose level.
Metabolite Screening in Plasma and Urine
Metabolite screening in plasma and urine after single dosing
Time frame: Plasma samples at pre-dose and 15, 30 and 45 min, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 48, 72 and 96 hours post dose at each dose level. Urine samples, pre-dose and for 24 hours post dose at each dose level
Effect of ODM-106 on Growth Hormone Levels
Growth hormone levels (Cmax) in serum after single oral dosing with either ODM-106 Capsule B, ODM-106 Capsule A or placebo.
Time frame: Predose and 1, 2, 3,4, 6 and 8 hours post dose at each dose level.
Sedation Scores on a Visual Analogue Scale (VAS)
Assessment of sedation by subject
Time frame: Pre-dose and at 1, 6 and 10.5h post dose at each dose level
Dexterity and Reaction Times
Selected battery of psychomotor tests
Time frame: Pre-dose and at 1 and 6h post dose at each dose level
Quantitative EEG
Quantitative analysis of EEG
Time frame: Pre-dose and at 1, 6 and 10 h post dose at each dose level
Healthy male volunteers were recruited
| Milestone | Panel 1 | Panel 2 |
|---|---|---|
| Started | 9 | 9 |
| Period 1 | 8 | 8 |
| Period 2 | 8 | 8 |
| Period 3 | 8 | 8 |
| Period 4 | 8 | 8 |
| Completed | 8 | 8 |
| Not completed | 1 | 1 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 |
Clinically relevant changes from baseline in safety laboratory assessments (haematology, clinical chemistry, urinalysis), vital signs (pulse and heart rate), 12 lead electrocardiograms, Holter electrocardiograms, telemetry, physical examination.
| subjects affected | ODM-106 Capsule B 2mg | ODM-106 Capsule B 10mg | ODM-106 Capsule B 25mg | ODM-106 Capsule B 50mg | ODM-106 Capsule B 100mg (1 x 100mg) | ODM-106 Capsule B 100mg (10 x 10mg) | ODM-106 Capsule B 200mg | ODM-106 Capsule A 100mg | Placebo |
|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With Adverse Events as a Measure of Safety. Number of Participants With Adverse Events Related to Tolerability. | 0 | 4 | 5 | 1 | 2 | 1 | 3 | 2 | 3 |
cMax of ODM-106 after single dosing of either Capsule B or Capsule A
| ng/ml | ODM-106 Capsule B 2mg | ODM-106 Capsule B 10mg | ODM-106 Capsule B 25mg | ODM-106 Capsule B 50mg | ODM-106 Capsule B 100mg (1 x 100mg) | ODM-106 Capsule B 100mg (10 x 10mg) | ODM-106 Capsule B 200mg | ODM-106 Capsule A 100mg | Placebo |
|---|---|---|---|---|---|---|---|---|---|
| Peak Plasma Concentration (cMax) of ODM-106 | 9.1 ± 4.2 | 18.4 ± 11.4 | 67.8 ± 51.7 | 119.2 ± 60.1 | 22.0 ± 20.1 | 225.9 ± 177.2 | 547.7 ± 319.5 | 8.3 ± 9.1 | — |
AUC of ODM-106 after single oral dosing of either Capsule B or Capsule A.
| h*ng/ml | ODM-106 Capsule B 2mg | ODM-106 Capsule B 10mg | ODM-106 Capsule B 25mg | ODM-106 Capsule B 50mg | ODM-106 Capsule B 100mg (1 x 100mg) | ODM-106 Capsule B 100mg (10 x 10mg) | ODM-106 Capsule B 200mg | ODM-106 Capsule A 100mg | Placebo |
|---|---|---|---|---|---|---|---|---|---|
| Area Under the Plasma Concentration Versus Time Curve (AUC) of ODM-106 | 16.9 ± 8.8 | 61.3 ± 44.1 | 213.8 ± 78.7 | 559.4 ± 310.9 | 297.4 ± 346.3 | 1089.2 ± 977.0 | 2850.8 ± 2319.8 | 82.0 ± 64.7 | — |
tmax of ODM-106 after single oral dosing of Capsule B or Capsule A
| h | ODM-106 Capsule B 2mg | ODM-106 Capsule B 10mg | ODM-106 Capsule B 25mg | ODM-106 Capsule B 50mg | ODM-106 Capsule B 100mg (1 x 100mg) | ODM-106 Capsule B 100mg (10 x 10mg) | ODM-106 Capsule B 200mg | ODM-106 Capsule A 100mg | Placebo |
|---|---|---|---|---|---|---|---|---|---|
| Time to Peak Plasma Concentration (Tmax) of ODM-106 | 0.7 (0.5 to 1.0) | 1.9 (1.5 to 3.0) | 1.5 (0.5 to 3.0) | 2.1 (0.8 to 3.5) | 5.8 (1.5 to 23.9) | 1.5 (0.8 to 3.5) | 1.5 (0.8 to 3.5) | 3.0 (1.5 to 4.0) | — |
Elimination half-life of ODM-106 after single dosing of either Capsule B or Capsule A
| h | ODM-106 Capsule B 2mg | ODM-106 Capsule B 10mg | ODM-106 Capsule B 25mg | ODM-106 Capsule B 50mg | ODM-106 Capsule B 100mg (1 x 100mg) | ODM-106 Capsule B 100mg (10 x 10mg) | ODM-106 Capsule B 200mg | ODM-106 Capsule A 100mg | Placebo |
|---|---|---|---|---|---|---|---|---|---|
| Elimination Half-life of ODM-106 | 9.5 ± 5.5 | 20.6 ± 12.7 | 23.0 ± 2.1 | 27.3 ± 4.7 | 23.5 ± 6.3 | 27.4 ± 9.2 | 32.1 ± 10.0 | 21.7 ± 3.2 | — |
Metabolite screening in plasma and urine after single dosing
Results for this outcome have not been posted.
Growth hormone levels (Cmax) in serum after single oral dosing with either ODM-106 Capsule B, ODM-106 Capsule A or placebo.
| ng/ml | ODM-106 Capsule B 2mg | ODM-106 Capsule B 10mg | ODM-106 Capsule B 25mg | ODM-106 Capsule B 50mg | ODM-106 Capsule B 100mg (1 x 100mg) | ODM-106 Capsule B 100mg (10 x 10mg) | ODM-106 Capsule B 200mg | ODM-106 Capsule A 100mg | Placebo |
|---|---|---|---|---|---|---|---|---|---|
| Effect of ODM-106 on Growth Hormone Levels | 1.7 ± 3.2 | 0.47 ± 1.04 | 1.05 ± 2.88 | 1.93 ± 1.99 | 0.8 ± 1.36 | 2.23 ± 6.12 | 0.82 ± 0.68 | 4.14 ± 4.96 | 1.01 ± 2.45 |
Assessment of sedation by subject
Results for this outcome have not been posted.
Selected battery of psychomotor tests
Results for this outcome have not been posted.
Quantitative analysis of EEG
Results for this outcome have not been posted.
Collected over From the start of study treatment until the end of study visit (approximately 12-16 weeks). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ODM-106 Capsule B 2mg | — | 0/6 (0%) | 0/6 (0%) |
| ODM-106 Capsule B 10mg | — | 0/6 (0%) | 4/6 (66.7%) |
| ODM-106 Capsule B 25mg | — | 0/6 (0%) | 5/6 (83.3%) |
| ODM-106 Capsule B 50mg | — | 0/6 (0%) | 1/6 (16.7%) |
| ODM-106 Capsule B 100mg (1 x 100mg) | — | 0/6 (0%) | 2/6 (33.3%) |
| ODM-106 Capsule B 100mg (10 x 10mg) | — | 0/6 (0%) | 1/6 (16.7%) |
| ODM-106 Capsule B 200mg | — | 0/6 (0%) | 3/6 (50%) |
| ODM-106 Capsule A 100mg | — | 0/6 (0%) | 2/6 (33.3%) |
| Placebo | — | 0/16 (0%) | 3/16 (18.8%) |
| Event | ODM-106 Capsule B 2mg | ODM-106 Capsule B 10mg | ODM-106 Capsule B 25mg | ODM-106 Capsule B 50mg | ODM-106 Capsule B 100mg (1 x 100mg) | ODM-106 Capsule B 100mg (10 x 10mg) | ODM-106 Capsule B 200mg | ODM-106 Capsule A 100mg | Placebo |
|---|---|---|---|---|---|---|---|---|---|
| HEADACHENervous system disorders | 0/6 | 1/6 | 4/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 1/16 |
| NASOPHARYNGITISInfections and infestations | 0/6 | 1/6 | 1/6 | 0/6 | 0/6 | 0/6 | 3/6 | 0/6 | 0/16 |
| SUNBURNInjury, poisoning and procedural complications | 0/6 | 0/6 | 1/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/16 |
| RHYTHM IDIOVENTRICULARCardiac disorders | 0/6 | 1/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/16 |
| VENTRICULAR EXTRASYSTOLESCardiac disorders | 0/6 | 1/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/16 |
| EPISTAXISRespiratory, thoracic and mediastinal disorders | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 1/6 | 1/6 | 0/6 | 0/16 |
| NASAL DRYNESSRespiratory, thoracic and mediastinal disorders | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 1/6 | 1/6 | 0/6 | 0/16 |
| OROPHARYNGEAL PAINRespiratory, thoracic and mediastinal disorders | 0/6 | 1/6 | 0/6 | 0/6 | 1/6 | 0/6 | 0/6 | 0/6 | 0/16 |
| PRODUCTIVE COUGHRespiratory, thoracic and mediastinal disorders | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 1/6 | 0/16 |
| DISTURBANCE IN ATTENTIONNervous system disorders | 0/6 | 0/6 | 1/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/16 |
| Age, Categorical(Participants) | Panel 1 | Panel 2 | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 9 | 9 | 18 |
| >=65 years | 0 | 0 | 0 |
| Gender(Participants) | Panel 1 | Panel 2 | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 9 | 9 | 18 |
| Region of Enrollment(participants) | Panel 1 | Panel 2 | Total |
|---|---|---|---|
| Germany | 9 | 9 | 18 |
The record gives a start of Mar 2015, a primary completion of Oct 2015 and a completion of Mar 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2016, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Orion Corporation, Orion Pharma →